Xencor Reports Presentation Of Results From Its Phase 1a Single-Ascending Dose Study Of XmAb 564 In Healthy Volunteers; Engineered IL2-Fc Cytokine Is Well-tolerated
Portfolio Pulse from Benzinga Newsdesk
Xencor has reported positive results from its Phase 1a single-ascending dose study of XmAb 564 in healthy volunteers, showing that the engineered IL2-Fc cytokine is well-tolerated. The company is enrolling patients for the Phase 1b study in atopic dermatitis and psoriasis, with dose escalation completion expected in early 2024.
May 30, 2023 | 10:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xencor's positive Phase 1a results for XmAb 564 indicate the engineered IL2-Fc cytokine is well-tolerated, potentially benefiting the company's ongoing Phase 1b study.
The positive results from the Phase 1a study indicate that XmAb 564 is well-tolerated in healthy volunteers, which is a crucial step in the drug development process. This increases the likelihood of success in the ongoing Phase 1b study, which could lead to further development and potential commercialization of the drug. As a result, this news is likely to have a positive impact on Xencor's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100